Resmed.
manufacturer of CPAP masks, machines and products that diagnose, treat or help manage respiratory conditions
- Reports this week
- 1
- Active events
- 0
- Connections
- 85
What's happening
Earlier this month
-
MarketBeat reported analyst ratings for ResMed and Abbott Laboratories on October 1, 2026.Some support1 report
-
ResMed (Australia) emphasized the success of its new product rollouts and R&D investments.Some support3 reports
-
Oura announces partnerships with Dexcom and Resmed for health feature integration, while noting that regulatory uncertainty affects its product scope.Some support1 report
One to three months ago
-
Resmed discussed its growth outlook in the Americas, highlighting the use of Snap's automated resupply technology during a meeting with Morgan Stanley.Some support1 report
-
Resmed and Koninklijke Philips NV face market challenges due to reduced need for sleep apnea treatments, coupled with a competitor re-entering the U.S. market.Well supported3 reports
-
Resmed and Milestone Scientific Inc. are being compared by analysts regarding their financial metrics.Some support1 report
-
Ron Taylor is retiring after 21 years of service and is being appointed to a lead director role at Resmed.Some support1 report
-
Resmed and Astral devices faced cost increases and required a $42 million charge, impacting operating margins, according to analysts.Some support1 report
-
A company listed on the London Stock Exchange is facing a Class 1 recall notice due to safety concerns, with financial performance reported via market data.Some support1 report
-
On August 1, 2026, key partnerships were established involving MAS, including roles as a central bank partner, a hub for digital identity in Asia, and a driver of growth for medical device companies like Resmed.Some support1 report
-
Resmed announced its utilization of Dawn as a new generative AI health concierge while operating in the Americas, with RBC Capital Markets providing analyst coverage.Some support2 reports
Gone quiet
No new reports in 90+ days-
Michael J. Farrell, while serving as CEO, sold shares in Resmed on July 9, 2025.Well supported4 reports
-
Analyst discusses market risks facing ResMed stock.Some support1 report1 development inside
-
Analysts are reviewing Resmed's divestiture and acquisition strategy, noting long-term benefits despite near-term EPS dilution.Some support1 report1 development inside
-
Resmed is headquartered in San Diego, California.Some support1 report
-
Resmed sold its MatrixCare business to Frazier Healthcare Partners on July 1, 2026.Some support1 report1 development inside
-
Resmed released its financial results after the New York Stock Exchange closed.Some support1 report
-
Zacks Investment Research provided stock analysis and ratings for ResMed (Australia) on August 27, 2025.Some support3 reports
-
Justin Leong was appointed Chief Product Officer at ResMed.Some support1 report
-
Akebia Therapeutics' earnings outlook improved and was noted for outperforming peers, while ResMed was also reported for outperforming the medical sector.Some support1 report
-
ResMed outperformed sector and industry averages by 16.9% and holds a Value Score of C, according to Zacks Medical.Some support2 reports
-
ResMed shares outperformed the S&P 500 on August 28, 2025.Well supported3 reports
-
The industry growth forecast is 8.2%, and ResMed's specific forecast is 7.1%.Some support1 report
-
Investors focused on stock price and earnings trends involving Momentum (Q68797150) and ResMed (Australia) on July 24, 2025.Some support1 report
-
ResMed (Australia) tracked overall market performance on July 15, 2025.Some support1 report
-
Getinge AB, ResMed (Australia), and Koninklijke Philips N.V. are leading the ventilator market through innovation.Some support2 reports
-
ResMed (Australia) received a rating upgrade following an upward trend in its earnings estimates on June 26, 2025.Speculative1 report
-
Resmed reported revenue increases for devices and masks in Europe in August 2025.Some support1 report
-
Resmed operates its SaaS business in the United States and Germany.Some support2 reports
-
Resmed announced board appointments and executive changes on August 19, 2025, including Nicole Mowad-Nassar joining the board.Some support1 report
-
Resmed conducted a study projecting a rise in Obstructive Sleep Apnea (OSA) in the US, with CMO Carlos Nunez as a co-author.Some support1 report1 development inside
-
Resmed announced details about AirTouch N30i, a nasal cradle mask product designed to help patients manage Obstructive Sleep Apnea (OSA).Some support2 reports
-
The World Sleep Congress is being held in Singapore on September 4, 2025, involving Resmed.Some support1 report1 development inside
-
Resmed reported 11% top-line growth in Europe, alongside strong performance in the U.S. and Canada.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Resmed this week
News at the entities that move Resmed most-
FDA StructuralFDA approval supports NDA submission in Aurora.Moves Resmed
-
London Stock Exchange StructuralMetals One Plc holds gold and uranium exploration interests and is listed on the AIM Market.Moves Resmed
-
Morgan Stanley OperationalMarketBeat, Morgan Stanley, and Citigroup provided recent stock rating data for Geberit.Moves Resmed
-
inflation StructuralCentral banks are struggling to contain inflation, and the article argues that gold is not a reliable hedge against rising prices.Moves Resmed
-
Snap Inc. StructuralFisher Investments offered retirement income guides while also noting that Meta is more profitable than Alphabet and Snap.Moves Resmed
-
New York Stock Exchange StructuralFifth Third Bancorp purchased a new stake in the Western Asset Global Corporate Defined Opportunity Fund Inc. on October 22, 2026.Moves Resmed
Connections
The 29 strongest of 85, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Mick Farrell Structural
Mick Farrell holds the formal leadership roles of Chairman and CEO at Resmed.
-
London Stock Exchange Structural
Resmed is publicly traded on the London Stock Exchange, relying on its infrastructure for market valuation and liquidity.
-
Michael J. Farrell Structural
Michael J. Farrell holds the executive role of CEO at Resmed.
-
New York Stock Exchange Structural
Resmed operates as a publicly traded company whose market functions are governed by the rules of the New York Stock Exchange.
-
Dawn Structural
Resmed utilizes Dawn as a generative AI health concierge service.
-
Michael Farrell Structural
A's professional actions are described as driving the growth of the medical device company B in Singapore.
-
Dawn Structural
Dawn functions as a generative AI agent for Resmed.
-
FDA Structural
The FDA regulates Resmed, resulting in an investigation and a Class 1 recall notice.
Show all 29 connections
-
Astral Transactional
Resmed has taken a charge for devices supplied by Astral, which are currently facing safety concerns and recall.
-
Oura Operational
Oura and Resmed have formed a partnership to integrate health features into their respective products.
-
Baxter International Operational
The two companies are actively competing within the specialized healthcare equipment market segment.
-
Koninklijke Philips NV Operational
The two companies are potential competitors facing re-entry into the U.S. medical device market.
-
Snap Inc. Structural
Resmed is integrating Snap's automated resupply technology into its operations.
-
Morgan Stanley Operational
Morgan Stanley influenced ResMed's market standing by issuing a stock downgrade citing profit margin concerns.
-
Tyler Reddick Operational
Tyler Reddick collaborates with Resmed to promote health awareness.
-
WHOOP Operational
The relationship is based on partnerships where users are referred to Resmed products.
-
Dexcom Mentioned together
Both companies are grouped thematically within the healthcare equipment segment.
-
RBC Capital Markets Mentioned together
RBC Capital Markets provides analyst coverage and rating updates on Resmed.
-
inflation Structural
Inflationary pressures manifest as cost increases that directly impact Resmed's operating margins.
-
Abbott Laboratories Mentioned together
Both Abbott Laboratories and Resmed are categorized as large-cap healthcare companies.
-
Europe Shared context
Resmed reports financial growth and revenue increases within the European market.
-
Medicare Operational
The scale and operational dynamics of the Medicare program influence the cost structure and premium increases relevant to Resmed's market.
-
Social Security Shared context
Resmed operates within the broader healthcare market context influenced by Social Security's benefit structure.
-
Osa Shared context
Resmed develops masks for the treatment of Obstructive Sleep Apnea (OSA).
-
Americas Shared context
Resmed conducts business operations within the Americas market segment.
-
San Diego Shared context
ResMed is headquartered in San Diego, California.
-
Goldman Sachs Mentioned together
Both companies were mentioned in the context of analysts seeking clarity on revenue growth drivers.
-
William Blair Transactional
The relationship is characterized by an analyst's view regarding a divestiture, which is viewed as a long-term benefit.
-
Peter Switzer Mentioned together
The evidence is insufficient to define a relationship between Peter Switzer and Resmed beyond a potential, unproven market context.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
3 events- Oura announces partnerships with Dexcom and Resmed for health feature integration, while noting that regulatory uncertainty affects its product scope.
- Resmed discussed its growth outlook in the Americas, highlighting the use of Snap's automated resupply technology during a meeting with Morgan Stanley.
- Resmed and Milestone Scientific Inc. are being compared by analysts regarding their financial metrics.
August 2026
5 events- Ron Taylor is retiring after 21 years of service and is being appointed to a lead director role at Resmed.
- Resmed and Astral devices faced cost increases and required a $42 million charge, impacting operating margins, according to analysts.
- A company listed on the London Stock Exchange is facing a Class 1 recall notice due to safety concerns, with financial performance reported via market data.
- On August 1, 2026, key partnerships were established involving MAS, including roles as a central bank partner, a hub for digital identity in Asia, and a driver of growth for medical device companies like Resmed.
- Resmed announced its utilization of Dawn as a new generative AI health concierge while operating in the Americas, with RBC Capital Markets providing analyst coverage.
Show 2 earlier months
July 2026
4 events- Analyst discusses market risks facing ResMed stock.
- Analysts are reviewing Resmed's divestiture and acquisition strategy, noting long-term benefits despite near-term EPS dilution.
- Resmed is headquartered in San Diego, California.
- Resmed sold its MatrixCare business to Frazier Healthcare Partners on July 1, 2026.
June 2026
21 events- ResMed (Australia) emphasized the success of its new product rollouts and R&D investments.
- Resmed and Koninklijke Philips NV face market challenges due to reduced need for sleep apnea treatments, coupled with a competitor re-entering the U.S. market.
- Michael J. Farrell, while serving as CEO, sold shares in Resmed on July 9, 2025.
- Resmed released its financial results after the New York Stock Exchange closed.
- Zacks Investment Research provided stock analysis and ratings for ResMed (Australia) on August 27, 2025.
- Justin Leong was appointed Chief Product Officer at ResMed.
- Akebia Therapeutics' earnings outlook improved and was noted for outperforming peers, while ResMed was also reported for outperforming the medical sector.
- ResMed outperformed sector and industry averages by 16.9% and holds a Value Score of C, according to Zacks Medical.
- ResMed shares outperformed the S&P 500 on August 28, 2025.
- The industry growth forecast is 8.2%, and ResMed's specific forecast is 7.1%.
- Investors focused on stock price and earnings trends involving Momentum (Q68797150) and ResMed (Australia) on July 24, 2025.
- ResMed (Australia) tracked overall market performance on July 15, 2025.
- Getinge AB, ResMed (Australia), and Koninklijke Philips N.V. are leading the ventilator market through innovation.
- ResMed (Australia) received a rating upgrade following an upward trend in its earnings estimates on June 26, 2025.
- Resmed reported revenue increases for devices and masks in Europe in August 2025.
- Resmed operates its SaaS business in the United States and Germany.
- Resmed announced board appointments and executive changes on August 19, 2025, including Nicole Mowad-Nassar joining the board.
- Resmed conducted a study projecting a rise in Obstructive Sleep Apnea (OSA) in the US, with CMO Carlos Nunez as a co-author.
- Resmed announced details about AirTouch N30i, a nasal cradle mask product designed to help patients manage Obstructive Sleep Apnea (OSA).
- The World Sleep Congress is being held in Singapore on September 4, 2025, involving Resmed.
- Resmed reported 11% top-line growth in Europe, alongside strong performance in the U.S. and Canada.